95 related articles for article (PubMed ID: 35749808)
1. Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma.
Rimini M; Macarulla T; Burgio V; Lonardi S; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Nappo F; Nichetti F; Lai E; Valgiusti M; Cappetta A; Febregat C; Fassan M; De Braud F; Puzzoni M; Frassineti GL; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Eur J Cancer; 2022 Aug; 171():232-241. PubMed ID: 35749808
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
Chae H; Kim D; Yoo C; Kim KP; Jeong JH; Chang HM; Lee SS; Park DH; Song TJ; Hwang S; Kim KH; Song GW; Ahn CS; Lee JH; Hwang DW; Kim SC; Jang SJ; Hong SM; Kim TW; Ryoo BY
Eur J Cancer; 2019 Oct; 120():31-39. PubMed ID: 31476489
[TBL] [Abstract][Full Text] [Related]
3. Platinum Sensitivity in
Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
[TBL] [Abstract][Full Text] [Related]
4. Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy.
Uson Junior PLS; Majeed U; Yin J; Botrus G; Sonbol MB; Ahn DH; Starr JS; Jones JC; Babiker H; Inabinett SR; Wylie N; Boyle AWR; Bekaii-Saab TS; Gores GJ; Smoot R; Barrett M; Nagalo B; Meurice N; Elliott N; Petit J; Zhou Y; Arora M; Dumbauld C; Barro O; Baker A; Bogenberger J; Buetow K; Mansfield A; Mody K; Borad MJ
JCO Precis Oncol; 2022 Jun; 6(1):e2100274. PubMed ID: 35666960
[TBL] [Abstract][Full Text] [Related]
5. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
6. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
Rimini M; Fabregat-Franco C; Persano M; Burgio V; Bergamo F; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Target Oncol; 2023 Jan; 18(1):139-145. PubMed ID: 36689074
[TBL] [Abstract][Full Text] [Related]
7. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
[TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of BRCA Mutations in Advanced Biliary Tract Cancer.
Kim H; Kim JY; Park KU
Oncology; 2023; 101(1):41-48. PubMed ID: 36257294
[TBL] [Abstract][Full Text] [Related]
9. Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.
Tang TY; Nichetti F; Kaplan B; Lonardi S; Pietrantonio F; Salvatore L; Vivaldi C; Rimassa L; de Braud F; Rizzato MD; Pavlick D; Chu R; Danner De Armas A; Sharaf R; Sokol E; Rodon Ahnert J; Ross JS; Javle M; Niger M
Clin Cancer Res; 2023 Dec; 29(23):4853-4862. PubMed ID: 37773629
[TBL] [Abstract][Full Text] [Related]
10. BRCAness in biliary tract cancer: a new prognostic and predictive biomarker?
Hachem S; Kassis Y; Hachem MC; Zouein J; Gharios J; Kourie HR
Biomark Med; 2023 Jan; 17(1):51-57. PubMed ID: 36994675
[TBL] [Abstract][Full Text] [Related]
11. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.
Kinzler MN; Jeroch J; Klasen C; Himmelsbach V; Koch C; Finkelmeier F; Trojan J; Zeuzem S; Pession U; Reis H; Demes MC; Wild PJ; Walter D
J Cancer Res Clin Oncol; 2023 Aug; 149(9):6391-6398. PubMed ID: 36757619
[TBL] [Abstract][Full Text] [Related]
12. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
13. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.
Mody K; Jain P; El-Refai SM; Azad NS; Zabransky DJ; Baretti M; Shroff RT; Kelley RK; El-Khouiery AB; Hockenberry AJ; Lau D; Lesinski GB; Yarchoan M
JCO Precis Oncol; 2022 Jun; 6():e2100510. PubMed ID: 35675577
[TBL] [Abstract][Full Text] [Related]
14. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
Yoon JG; Kim MH; Jang M; Kim H; Hwang HK; Kang CM; Lee WJ; Kang B; Lee CK; Lee MG; Chung HC; Choi HJ; Park YN
Hepatology; 2021 Oct; 74(4):1914-1931. PubMed ID: 33884649
[TBL] [Abstract][Full Text] [Related]
15. Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.
Rimini M; Fabregat-Franco C; Burgio V; Lonardi S; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
Sci Rep; 2022 Nov; 12(1):18775. PubMed ID: 36335135
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience.
Wang L; Zhu H; Zhao Y; Pan Q; Mao A; Zhu W; Zhang N; Lin Z; Zhou J; Wang Y; Zhang Y; Wang M; Feng Y; He X; Xu W; Wang L
J Transl Med; 2020 Jul; 18(1):273. PubMed ID: 32631434
[TBL] [Abstract][Full Text] [Related]
17. Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Lin PH; Chen M; Tsai LW; Lo C; Yen TC; Huang TY; Chen CK; Fan SC; Kuo SH; Huang CS
Cancer Sci; 2020 Apr; 111(4):1375-1384. PubMed ID: 31958182
[TBL] [Abstract][Full Text] [Related]
18. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
Tomczak A; Springfeld C; Dill MT; Chang DH; Kazdal D; Wagner U; Mehrabi A; Brockschmidt A; Luedde T; Naumann P; Stenzinger A; Schirmacher P; Longerich T
Br J Cancer; 2022 Nov; 127(9):1701-1708. PubMed ID: 35986087
[TBL] [Abstract][Full Text] [Related]
19. Treatments, prognostic factors, and genetic heterogeneity in advanced cholangiocarcinoma: A multicenter real-world study.
Ottaiano A; Santorsola M; Diana A; Belli A; Lentini Graziano ML; Orefice J; Patrone R; Di Mauro A; Scognamiglio G; Tatangelo F; De Bellis M; Piccirillo M; Fiore F; Stilo S; Tarotto L; Correra M; Di Lorenzo S; Capuozzo M; Avallone A; Silvestro L; Bianco A; Granata V; Federico P; Montesarchio V; Daniele B; Izzo F; Nasti G
Cancer Med; 2024 Feb; 13(4):e6892. PubMed ID: 38457226
[TBL] [Abstract][Full Text] [Related]
20. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
